Novo CEO says setbacks demand faster research, purchases

Novo Nordisk's CEO Mike Doustdar sought to reassure investors today that the drugmaker can rebuild its pipeline, pledging faster research and bolt-on acquisitions after an upgraded 2026 outlook failed to lift sentiment.